Solid Biosciences (SLDB) Change in Accured Expenses (2017 - 2026)

Solid Biosciences has reported Change in Accured Expenses for 10 years, with the latest figure at -$473000.0 in Q1 2026.

• Quarterly Change in Accured Expenses fell 72.0% year-over-year to -$473000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.9 million (down 9.96% YoY) and the FY2025 annual result came in at $4.0 million, down 15.02% from the prior year.
• Change in Accured Expenses retreated to -$473000.0 in Q1 2026 per SLDB's latest filing, from $152000.0 in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $8.7 million in Q2 2022 and troughed at -$5.0 million in Q3 2022.
• A 5-year average of $424000.0 and a median of $152000.0 in 2025 frame the typical range for Change in Accured Expenses.
• The widest YoY moves for Change in Accured Expenses: up 1515.01% in 2022, down 1544.37% in 2022.
• Over 5 years, Change in Accured Expenses stood at $2.6 million in 2022, then sank by 164.03% to -$1.6 million in 2023, then surged by 198.72% to $1.6 million in 2024, then sank by 90.64% to $152000.0 in 2025, then sank by 411.18% to -$473000.0 in 2026.
• According to Business Quant data, Change in Accured Expenses over the past three periods registered -$473000.0, $152000.0, and $2.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.